Drug Profile
HBS 107
Latest Information Update: 08 Jan 2008
Price :
$50
*
At a glance
- Originator Hisamitsu Pharmaceutical
- Class
- Mechanism of Action Bile acid binding protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 19 Nov 2003 No development reported - Phase-II for Hypercholesterolaemia in Japan (PO)
- 11 Dec 2001 Investigation in Hypercholesterolaemia in Japan (PO)
- 14 Dec 2000 Phase-II clinical trials for Hypercholesterolaemia in Japan (PO)